2 results
Not approvedWill not start
The primary objective of this study is to demonstrate that the IOP-lowering efficacy of Travoprost Ophthalmic Solution, 0.004% (preserved with POLYQUAD) is noninferior to Timolol Ophthalmic Solution (0.5% or 0.25%) in pediatric glaucoma patients.
Approved WMOWill not start
The primary objective of the TactiFlex PAF IDE clinical trial is to demonstrate that ablation with the TactiFlex* Ablation Catheter, Sensor-Enabled* (TactiFlex SE), in conjunction with a compatible RF generator and three-dimensional mapping system,…